Altimmune (ALT) EBT Margin Growth (1y) (2011 - 2025)
Powered by 
Analysis
Altimmune (ALT) EBT Margin Growth (1y) (2011 - 2025) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn | -153.00 |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -571.00 |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn | 553.00 |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn | 4,709.00 |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - | - |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn | 1,076.00 |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn | 1,911.00 |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | -392.00 |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn | 29,565.00 |
| 10 | Altimmune | 626.82 Mn | 626.82 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 35.84 Mn |
| Sep 30, 2025 | 7.66 Mn |
| Jun 30, 2025 | 4.99 Mn |
| Mar 31, 2025 | 8.28 Mn |
| Dec 31, 2024 | -37.81 Mn |
| Sep 30, 2024 | -45.12 Mn |
| Jun 30, 2024 | -22.32 Mn |
| Mar 31, 2024 | -39.22 Mn |
| Dec 31, 2023 | -220,852.00 |
| Sep 30, 2023 | 117.99 Mn |
| Jun 30, 2023 | -1.79 Mn |
| Mar 31, 2023 | -3.46 Mn |
| Dec 31, 2022 | -8.26 Mn |
| Sep 30, 2022 | -116.44 Mn |
| Jun 30, 2022 | -23.35 Mn |
| Mar 31, 2022 | -5.93 Mn |
| Dec 31, 2021 | -26,494.00 |
| Sep 30, 2021 | -2.06 Mn |
| Jun 30, 2021 | -1.77 Mn |
| Mar 31, 2021 | -145,146.00 |